摘要:
The present invention relates to 5-membered ring heterocycles of the formula I, in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation and to their use as medicaments. The novel compounds are used as vitronectin receptor antagonists and as inhibitors of bone reabsorption.
摘要:
Compounds of the formula wherein the substituents are as defined in the application and their pharmaceutically acceptable acid and base salts thereof which are useful for preventing loss of bone matrix.
摘要:
There are described imino derivatives of formula (I)R.sup.1 --Y--A--B--D--E--F--G (I)their preparation and their use as medicaments. The compounds according to the invention may be used as vitronectin receptor antagonists and as inhibitors of bone resorption.
摘要:
The invention concerns prodrugs of enzyme inhibitors in which at least one OH-- group in the enzyme inhibitor has been converted into a derivative grouping of the formula III, IV or V: ##STR1## in which the groups R.sup.11 to R.sup.25 and s,l, m, o, q, and r are as defined in the description. Such prodrugs exhibit an improved solubility in water and improved pharmaco-kinetic characteristics.
摘要:
The invention relates to compounds of the formula I ##STR1## in which A denotes hydrogen or an amino protective group, B denotes one or more amino acids, X denotes alkylene or aralkylene, Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are identical or different and denote hydrogen, methyl, methoxy or nitro, V denotes hydrogen or a carboxyl protective group, W denotes --[CH.sub.2 ].sub.n -- or --O--[CH.sub.2 ].sub.n --, m denotes 0 or 1, n denotes 0 to 6, and p denotes 0 to 5, to a process for their preparation. The compounds of formula I are useful as linkage agents or anchor groups in the solid-phase synthesis of peptide aminoalkylamides and peptide hydrazides.
摘要:
What are disclosed are prostacylin PGI.sub.2 analogs of the formula ##STR1## having a more specific or longer lasting pharmacological action than PGI.sub.2, methods of making these analogs; and methods and pharmaceutical preparations for inhibiting blood platelet aggregation, for treating hypertension, for the treatment or prophylaxis of gastrointestinal ulcers, and for the treatment of asthma.